Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre, Randomized, Double-blind, Parallel Group Phase III Study to Assess Efficacy and Safety of Dymista® Compared to Azep® and Flixonase® Nasal Sprays in the Treatment of Chinese Patients With Allergic Rhinitis/Rhinoconjunctivitis

NCT03599791 is registered in ClinicalTrials.gov with MEDA Pharma GmbH & Co. KG as lead sponsor.

NCT NCT03599791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03599791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre, Randomized, Double-blind, Parallel Group Phase III Study to Assess Efficacy and Safety of Dymista® Compared to Azep® and Flixonase® Nasal Sprays in the Treatment of Chinese Patients With Allergic Rhinitis/Rhinoconjunctivitis
Lead sponsor
MEDA Pharma GmbH & Co. KG
Phase
Phase 3
Overall status
Completed
Start date
June 29, 2018
Completion date
September 24, 2019
Enrollment
900 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis